GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (STU:7CC) » Definitions » Cyclically Adjusted Price-to-FCF

Check-Cap (STU:7CC) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Check-Cap Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Check-Cap Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Check-Cap's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Check-Cap Cyclically Adjusted Price-to-FCF Chart

Check-Cap Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Check-Cap Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Check-Cap's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Check-Cap's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Check-Cap's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Check-Cap's Cyclically Adjusted Price-to-FCF falls into.


;
;

Check-Cap Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Check-Cap's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Check-Cap's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0/132.5538*132.5538
=0.000

Current CPI (Jun. 2024) = 132.5538.

Check-Cap Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 -73.364 99.621 -97.617
201506 -20.945 100.684 -27.575
201509 -42.655 100.392 -56.320
201512 -38.571 99.792 -51.234
201603 -40.855 100.470 -53.901
201606 -38.455 101.688 -50.127
201609 -22.719 101.861 -29.565
201612 -29.768 101.863 -38.737
201703 -33.176 102.862 -42.752
201706 -34.271 103.349 -43.955
201709 -20.814 104.136 -26.494
201712 -25.273 104.011 -32.208
201803 -22.583 105.290 -28.431
201806 -11.547 106.317 -14.397
201809 -7.903 106.507 -9.836
201812 -9.295 105.998 -11.624
201903 -9.329 107.251 -11.530
201906 -5.684 108.070 -6.972
201909 -7.133 108.329 -8.728
201912 -7.249 108.420 -8.863
202003 -6.331 108.902 -7.706
202006 -2.296 108.767 -2.798
202009 -1.389 109.815 -1.677
202012 -1.274 109.897 -1.537
202103 -0.826 111.754 -0.980
202106 -1.100 114.631 -1.272
202109 -0.816 115.734 -0.935
202112 -0.839 117.630 -0.945
202203 -0.897 121.301 -0.980
202206 -0.904 125.017 -0.959
202209 -0.741 125.227 -0.784
202212 -0.684 125.222 -0.724
202303 -0.750 127.348 -0.781
202306 -0.823 128.729 -0.847
202309 -0.575 129.860 -0.587
202312 -0.555 129.419 -0.568
202406 0.000 132.554 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Check-Cap  (STU:7CC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Check-Cap Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Check-Cap's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Check-Cap Business Description

Traded in Other Exchanges
Address
29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Check-Cap Headlines

No Headlines